The Biotech Growth Trust PLC (LSE:BIOG) has been buying back its own shares regularly throughout 2026, according to its frequent regulatory announcements, even as its portfolio has benefited from a wave of biotechnology takeovers. The central question is how the trust is combining repurchases with an M&A-rich portfolio, and what its recent figures show.
What the trust does
The Biotech Growth Trust, launched in June 1997, seeks Capital appreciation through Investment in the worldwide biotechnology industry. Its portfolio is managed by OrbiMed Advisors, with Geoffrey Hsu and Josh Golomb named as portfolio managers, while Frostrow Capital acts as alternative investment Fund Manager and company secretary. Performance is measured against the Nasdaq Biotechnology index on a net, total return, sterling-adjusted basis. As a closed-ended investment trust, its shares can trade above or below net asset value (NAV), and the board operates a discount control policy that, according to the annual report, triggers Buybacks when the discount exceeds 6%. No dividends are anticipated.
Latest announcements
The trust publishes daily NAV estimates and frequent buyback notices. On 25 September 2026, it reported buying 69,308 shares for cancellation at 1,578.19p each, under authority granted at the Annual General Meeting on 16 July 2026, leaving 18,815,240 shares in issue. In an announcement dated 28 September 2026, it put its estimated unaudited cum-income NAV at 1,650.82p per share at the close of Business on 25 September.
The monthly factsheet for August 2026, released on 14 September, reported NAV per share of 1,831p and a share price of 1,738p at 31 August, a discount of 5.1%, with net Assets of £347.6 million. During August the NAV rose 7.9% and the share price 8.5%, against a 9.8% rise in the benchmark. The manager noted that the sector had "meaningfully outperformed the broader market", but that a large rise in Moderna, which the trust does not hold, weighed on relative returns. Vertex Pharmaceuticals was the largest holding, at 4.6% of investments, among 94 holdings, with gearing of 8.2%.
Annual results and sector backdrop
The annual financial report for the year to 31 March 2026, published on 3 June 2026, showed a NAV total return of 73.4% and a share price total return of 67.1%, against 35.0% for the benchmark. NAV per share rose to 1,414.6p from 815.9p, and shareholders' funds reached £281.9 million. During the year the trust repurchased 7,183,277 shares at a cost of £69.5 million, at an average discount of 8.5%, which the report said added 2.8% to NAV return. Six portfolio companies were acquired during the year, including Avidity Biosciences by Novartis and Cidara Therapeutics by Merck. Further bids have followed, with the trust announcing takeovers of holdings by Biogen, ARCHIMED and GSK between April and June 2026.
Risks and what to watch
Biotechnology shares are sensitive to clinical trial outcomes, regulatory decisions, drug pricing policy and funding conditions, and the portfolio is concentrated in North America, which accounted for 86.0% at the end of August. Gearing magnifies both gains and losses, and the factsheet reported annual portfolio turnover of 215.6%, which is high. The daily NAV figures show that valuations can shift quickly: the late-September estimate was below the end-August factsheet figure. The next continuation vote is scheduled for the 2028 annual general meeting, and the size of the discount to NAV in coming months will likely influence how actively the board continues to buy back shares.
Conclusion
The Biotech Growth Trust is using regular buybacks, under its discount control policy, to manage the gap between share price and NAV while its OrbiMed-run portfolio has benefited from strong returns and repeated takeovers of holdings. Its published figures show substantial gains over the past year, although the sector's Volatility means results can change rapidly.






Please wait processing your request...